目的 觀察消癌平注射液聯(lián)合吉西他濱和卡鉑治療ⅢB和Ⅳ期非小細(xì)胞肺癌（NSCLC）的臨床療效。方法 選擇鄂東醫(yī)療集團(tuán)黃石市中心醫(yī)院2013年2月-2015年1月治療的ⅢB和Ⅳ期NSCLC患者106例，隨機(jī)分為吉西他濱和卡鉑化療對(duì)照組與消癌平注射液聯(lián)合吉西他濱和卡鉑化療觀察組，每組53例。比較兩組近遠(yuǎn)期臨床療效以及不良反應(yīng)。結(jié)果 治療4個(gè)周期后，觀察組的治療有效率和控制率分別為39.6%和77.4%；對(duì)照組的有效率和控制率分別為35.8%和75.5%，兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義。觀察組白細(xì)胞下降、血紅蛋白下降和血小板下降率分別為41.5%、37.7%和45.3%，顯著低于對(duì)照組的64.2%、62.3%和69.8%（P<0.05）。觀察組腎功能損傷、肝功能損傷、惡心、嘔吐、頭暈、頭痛、腹瀉和便秘發(fā)生率與對(duì)照組比較無(wú)顯著差異。觀察組中位生存時(shí)間8.4月，腫瘤進(jìn)展時(shí)間5.3個(gè)月，1年生存率26.4%；對(duì)照組中位生存時(shí)間7.7月，腫瘤進(jìn)展時(shí)間4.2個(gè)月，1年生存率為11.3%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 消癌平注射液聯(lián)合吉西他濱和卡鉑治療ⅢB和Ⅳ期NSCLC，可以降低化療藥的血液學(xué)毒性，提高遠(yuǎn)期臨床療效。

Objective To observe the clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in the treatment of IIIB and IV non-small cell lung cancer (NSCLC).Methods Totally 106 NSCLC patients from Huangshi Central Hospital of Edong Medical Group were sellected in this study. The patients were divided into gemcitabine and carboplatin control group (n=53) and Xiaoaiping Injection combined with gemcitabine and carboplatin observation group (n=53). The clinical efficacy and adverse reactions were compared between two groups.Results After four cycles of treatment, the effective rate and control rate in observation group were 39.6% and 77.4%, and those in control group were 35.8% and 75.5%. There was no significant difference between the two groups. The decline rates of white blood cells, hemoglobin, and platelet in observation group were 41.5%, 37.7%, and 45.3%, which were significantly lower than those of 64.2%, 62.3%, and 69.8% in control group (P<0.05). There was no significant difference of renal function injury, liver function damage, nausea, vomiting, dizziness, headache, diarrhea, and constipation between two groups. In observation group, the median survival time was 8.4 months, time to tumor progression was 5.3 months, and 1 year survival rate was 26.4%. In control group, the median survival time was 7.7 months, time to tumor progression was 4.2 months, and 1 year survival rate was 11.3%. There was significant difference between two groups (P<0.05).Conclusion Xiaoaiping Injection combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment of IIIB and IV NSCLC, and improve long-term clinical outcomes.combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment of IIIB and IV NSCLC, and improve long-term clinical outcomes.